Incyte (INCY, Biotechnology) Stock Valuation & Fair Value Mixed on our tests
Incyte (INCY, Biotechnology) trades at a blended P/E of 27.7, about 48% below its historical normal valuation, with a forward growth estimate of 39.1% and a PEG of 0.71. Analysts' one-year estimates have been hit 9% of the time. Priced at its historical normal P/E of 53.2 on the same blended earnings, the 2026-10-02 close of $115.30 corresponds to about $222 a share. This is a valuation reference, not a price target.
- Price $112.75 at the 2026-10-08 close, 6.9% below the 20-day average ($121.12) and 8.2% below the 50-day ($122.81).
- RSI (14) at 31.0.
- 52-week range $83.80 to $129.93: the price is 13.2% below the high and 34.5% above the low.
The Street vs SeerForecast
Wall Street's mean price target for INCY is $128.42 across 24 analysts, 13.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Misses analyst estimates often (73%)
Verdict history
tickerseer's rating moved from favorable on our tests (2026-06-10) to mixed on our tests (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 36 weeks
Frequently asked questions
Is Incyte stock overvalued?
At a blended P/E of 27.7 versus its historical normal P/E of 53.2, Incyte trades about 48% below its typical valuation, with a PEG of 0.71 on 39.1% forward growth. tickerseer currently rates it mixed on our tests.
What is Incyte's fair value and PEG?
Incyte trades at a blended P/E of 27.7 against a historical normal P/E of 53.2, a PEG of 0.71, and a forward growth estimate of 39.1%. Priced at its historical normal P/E of 53.2 on the same blended earnings, the 2026-10-02 close of $115.30 corresponds to about $222 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Incyte changed?
tickerseer's rating moved from favorable on our tests (2026-06-10) to mixed on our tests (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Incyte?
The mean Wall Street price target for Incyte is $128.42 across 24 analysts, 13.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.